Clinical Trials Logo

ALK Gene Rearrangement Positive clinical trials

View clinical trials related to ALK Gene Rearrangement Positive.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05122806 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

BIOEXALK
Start date: September 22, 2021
Phase: N/A
Study type: Interventional

BioEXALK is a prospective study evaluating the biological characteristics of advanced ALK-rearranged NSCLC treated with next generation TKIs in first line, included in the national EXPLORE ALK cohort (GFPC 03-2019), a non-interventional, national, multi-center cohort of ALK-rearranged NSCLC patients. BioExALK study will be proposed to every patient included in the Explore ALK GFPC 03-2019 study. Biological analysis will be performed on tumor tissue at diagnosis and at the time of disease progression when available and on circulating tumor DNA (ctDNA). For plasma testing, after obtained patient consent, blood samples will be taken and analyzed at the Léon Bérard Center (Lyon). Biological analysis on tissue obtained at diagnosis and at disease progression will be collected and be sent for centralized analysis to the Rouen University Hospital.

NCT ID: NCT04989322 Recruiting - Nsclc Clinical Trials

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Start date: October 5, 2021
Phase: Phase 2
Study type: Interventional

Adding chemotherapy or anti-VEGF to immunotherapy is an emerging strategy to enhance the efficacy of immunotherapy in many cancers. This phase 2 study aims to explore the preliminary efficacy of combination pembrolizumab with lenvatinib and chemotherapy in NSCLC patients with sensitizing EGFR, ALK, or ROS1 genetic aberration refractory to standard targeted therapy.

NCT ID: NCT04042558 Recruiting - NSCLC Stage IV Clinical Trials

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

GFPC 06-2018
Start date: September 26, 2019
Phase: Phase 2
Study type: Interventional

The objective of this study is to assess the efficacy of the combination of Platinum (carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage IIIB/IV non-squamous non-small cell lung cancer patients with progression-enhancing mutations following targeted therapies.